Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial.
Publication/Presentation Date
3-1-2023
Abstract
OBJECTIVE: To determine if treatment with a 5-HT3 antagonist (ondansetron) reduces need for opioid therapy in infants at risk for neonatal opioid withdrawal syndrome (NOWS).
STUDY DESIGN: A multicenter, randomized, placebo controlled, double blind clinical trial of ninety (90) infants. The intervention arms were intravenous ondansetron or placebo during labor followed by a daily dose of ondansetron or placebo in infants for five days.
RESULTS: Twenty-two (49%) ondansetron-treated and 26 (63%) placebo-treated infants required pharmacologic treatment (p > 0.05). The Finnegan score was lower in the ondansetron-treated group (4.6 vs. 5.6, p = 0.02). A non-significant trend was noted for the duration of hospitalization. There was no difference in need for phenobarbital or clonidine therapy, or total dose of morphine in the first 15 days of NOWS treatment.
CONCLUSIONS: Ondansetron treatment reduced the severity of NOWS symptoms; and there was an indication that it could reduce the length of stay.
CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT01965704.
Volume
43
Issue
3
First Page
271
Last Page
276
ISSN
1476-5543
Published In/Presented At
Peltz, G., Jansson, L. M., Adeniyi-Jones, S., Cohane, C., Drover, D., Shafer, S., Wang, M., Wu, M., Govindaswami, B., Jegatheesan, P., Argani, C., Khan, S., & Kraft, W. K. (2023). Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial. Journal of perinatology : official journal of the California Perinatal Association, 43(3), 271–276. https://doi.org/10.1038/s41372-022-01487-2
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
36030327
Department(s)
Administration and Leadership
Document Type
Article